Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia
Authors' conclusion
This study demonstrated considerable benefit of evinacumab for individuals with HoFH, with or without concurrent LA. Evinacumab appeared to lessen LA burden for some individuals.
Study context
- Population
- Participants with homozygous familial hypercholesterolaemia (HoFH) receiving evinacumab 15 mg/kg in Regeneron-sponsored clinical studies
- Participants
- 138 participants · 3 clinical studies
- Comparison
- Evinacumab with concurrent lipoprotein apheresis (LA) vs without LA
- LA at baselinen = 59
- No LA at baselinen = 79reference
- Primary endpoint
- Mean change in LDL-C from baseline
- Follow-up
- Week 24
Methodological detailsdescriptive
- Descriptive
Primary result
As reported in the abstract
LDL-C change from baseline
LA
−42.9
mean · SD 23.8 · %
No LA
−50.8
mean · SD 30.5 · %
Further findings
Low-density lipoprotein cholesterol (LDL-C) reduction across timepoints
- Reductions in LDL-C in both subgroups observed across all examined timepoints
Change in LA frequency (LA subgroup)
- LA frequency reduced
- 17 (29%)
- LA frequency increased
- 2 (3%)
Safety
Tolerability
- Evinacumab well-tolerated in both subgroups
Original publication
Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. Published 27 March 2026. doi:10.
Summarised from the published abstract; every number is checked against it